This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Who can participate
Inclusion criteria:
* A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
* Age ≥18 years at index date.
* With at least 12 months data availability prior to index date.
Exclusion criteria:
• Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.
БГ